
Month: September 2021
Most Read

Listen: Health equity ‘tourism,’ an $11B biopharma acquisition, & a bony Covid protest

STAT Plus: Genetic information can be messy. Mapping proteins could offer a clearer view of what’s driving cancer

STAT Plus: Key Senate committee considers a carveout for small biotech companies in drug pricing reforms

STAT Plus: Appeals court rules FDA ‘arbitrarily and capriciously’ approved a rare disease drug

Who telehealth isn’t reaching & Apple looks past A-fib

STAT Plus: With $11 billion Acceleron deal, new Merck CEO hopes to convince investors there is a lot more to the biopharma giant

Virtual Event: The evolving landscape for biosimilars
All Coverage














